缬沙坦对原发性高血压患者胰岛素抵抗及血清超敏C反应蛋白水平的影响  

The effectiveness of valsartan on the insulin resistance and hs-CRP of patients with essential hypertension

作　　者：许玉荣[1] 王淑珍[1] 赵丽丽[1] 薛新宏[1] 

机构地区：[1]唐山市截瘫疗养院内科,河北省唐山063000

出　　处：《中国基层医药》2013年第6期823-825,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察缬沙坦对原发性高血压患者胰岛素抵抗及超敏C反应蛋白（hs-CRP）水平的影响。方法130例原发性高血压患者随机分为两组，对照组65例，治疗组65例，对照组采用氨氯地平治疗，治疗组采用缬沙坦治疗，共治疗6个月，治疗后比较两组胰岛素抵抗和血清hs．CRP水平。结果两组治疗后收缩压和舒张压均较治疗前有明显降低（t=6．3706、6．4418、7．0519、7．2577，均P〈0．01），但两组治疗后血压差异均无统计学意义（均P〉0．05）；两组治疗后IR和hs—CRP均降低（t=6．3478、1．9977、4．0581、12．0722，均P〈0．01），且治疗组降低更明显（t=7．6049、4．6893，均P〈0．05）。结论缬沙坦有独立于降压之外的减少胰岛素抵抗和hs-CRP的作用。Objective To study the effectiveness of valsartan on the insulin resistance and high-sensitivity C-reactive protein（hs-CRP） of patients with essential hypertension. Methods One hundred and thirty patients with essential hypertension were randomly divided into two groups, the control group（ n =65 cases） and the treatment group （ n = 65 cases）. The patients in the control group were treated through amlodipine, while the patients in the treatment group were treated valsartan. They were all treated for six months. The insulin resistance（IR） and hs-CRP were com- pared. Results The systolic blood pressure and diastolic blood pressure were decreased after treatment in both groups （ t = 6. 3706,6.4418,7.0519,7. 2577, all P 〈 0.01 ）. There wasn＇t a significant difference between two groups （ P 〉 0.05）. The IR and hs-CRP were decreased in both groups （ t = 6. 3478,1. 9977,4. 0581,12. 0722, all P 〈 0.01 ）. There was a significant difference between two groups （ t = 7. 6049,4. 6893, all P 〈 0.05 ）. Conclusion Valsartan can improve the insulin resistance and hs-CRP, which weren＇t dependent on lowing blood pressure.

关 键 词：高血压 胰岛素抗药性 C反应蛋白质 缬沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]